Logo

Astute Medical Raises $6.2M in Series A Round

May 01, 2008
NEW YORK (GenomeWeb News) – Astute Medical said today that it has raised $6.2 million in a Series A round of financing led by De Novo Ventures.
 
San Diego-based Astute is developing protein biomarker-based tests for the rapid diagnosis and risk assessment of patients with hospital-acquired infections. The firm said it would use the funds from the first round of financing for research and development of the biomarkers.
 
Astute was founded last year and is led by CEO Christopher Hibberd, a former SVP of corporate development at Biosite, and CSO Paul McPherson, a former VP of research and development at Biosite, which was acquired last year for $1.7 billion by Inverness Medical Innovations.
 

Breaking News
The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.